Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Defining a role for c-Myc in breast tumorigenesis.

Nass SJ, Dickson RB.

Breast Cancer Res Treat. 1997 May;44(1):1-22. Review.

PMID:
9164674
2.

Tyrosine kinase receptor--nuclear protooncogene interactions in breast cancer.

Dickson RB, Salomon DS, Lippman ME.

Cancer Treat Res. 1992;61:249-73. Review.

PMID:
1360236
3.

Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer.

Musgrove EA, Sergio CM, Loi S, Inman CK, Anderson LR, Alles MC, Pinese M, Caldon CE, Schütte J, Gardiner-Garden M, Ormandy CJ, McArthur G, Butt AJ, Sutherland RL.

PLoS One. 2008 Aug 20;3(8):e2987. doi: 10.1371/journal.pone.0002987.

4.
6.

PEG10 is a c-MYC target gene in cancer cells.

Li CM, Margolin AA, Salas M, Memeo L, Mansukhani M, Hibshoosh H, Szabolcs M, Klinakis A, Tycko B.

Cancer Res. 2006 Jan 15;66(2):665-72.

8.

Involvement of Myc targets in c-myc and N-myc induced human tumors.

Ben-Yosef T, Yanuka O, Halle D, Benvenisty N.

Oncogene. 1998 Jul 16;17(2):165-71.

9.

Estrogen regulation of vascular endothelial growth factor in breast cancer in vitro and in vivo: the role of estrogen receptor alpha and c-Myc.

Dadiani M, Seger D, Kreizman T, Badikhi D, Margalit R, Eilam R, Degani H.

Endocr Relat Cancer. 2009 Sep;16(3):819-34. doi: 10.1677/ERC-08-0249. Epub 2009 Apr 27.

PMID:
19398483
10.

Regulation of human telomerase activity: repression by normal chromosome 3 abolishes nuclear telomerase reverse transcriptase transcripts but does not affect c-Myc activity.

Ducrest AL, Amacker M, Mathieu YD, Cuthbert AP, Trott DA, Newbold RF, Nabholz M, Lingner J.

Cancer Res. 2001 Oct 15;61(20):7594-602.

11.

Leptin-regulated gene expression in MCF-7 breast cancer cells: mechanistic insights into leptin-regulated mammary tumor growth and progression.

Perera CN, Chin HG, Duru N, Camarillo IG.

J Endocrinol. 2008 Nov;199(2):221-33. doi: 10.1677/JOE-08-0215. Epub 2008 Aug 20. Erratum in: J Endocrinol. 2008 Dec;199(3):499.

PMID:
18715880
12.

Amplification of c-myc gene and overexpression of c-Myc protein in breast cancer and adjacent non-neoplastic tissue.

Chrzan P, Skokowski J, Karmolinski A, Pawelczyk T.

Clin Biochem. 2001 Oct;34(7):557-62.

PMID:
11738392
13.

The proto-oncogene c-myc and apoptosis.

Hoffman B, Liebermann DA.

Oncogene. 1998 Dec 24;17(25):3351-7. Review.

14.

The Myc oncoprotein as a therapeutic target for human cancer.

Vita M, Henriksson M.

Semin Cancer Biol. 2006 Aug;16(4):318-30. Epub 2006 Aug 3. Review.

PMID:
16934487
15.

Growth factor-dependent regulation of survivin by c-myc in human breast cancer.

Cosgrave N, Hill AD, Young LS.

J Mol Endocrinol. 2006 Dec;37(3):377-90.

PMID:
17170079
16.

Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis.

Lawlor ER, Soucek L, Brown-Swigart L, Shchors K, Bialucha CU, Evan GI.

Cancer Res. 2006 May 1;66(9):4591-601.

17.

c-Myc in breast cancer.

Liao DJ, Dickson RB.

Endocr Relat Cancer. 2000 Sep;7(3):143-64. Review.

PMID:
11021963
18.

The functions of Myc in cell cycle progression and apoptosis.

Steiner P, Rudolph B, Müller D, Eilers M.

Prog Cell Cycle Res. 1996;2:73-82. Review.

PMID:
9552384
19.

Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models.

Jamerson MH, Johnson MD, Dickson RB.

Oncogene. 2000 Feb 21;19(8):1065-71. Review.

PMID:
10713691
20.

c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo.

Arango D, Corner GA, Wadler S, Catalano PJ, Augenlicht LH.

Cancer Res. 2001 Jun 15;61(12):4910-5.

Supplemental Content

Support Center